GPT and metabolic dysfunction-associated steatohepatitis: As a result, we believe that these three clinical parameters, including ALT, body weight, and HbA1c (ABC), can become the milestones in the treatment of NASH (Fig. 4), although the appropriate goal of each parameter to ameliorate hepatic fibrosis will be established.